167 related articles for article (PubMed ID: 37336036)
21. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections.
So YK; Son YI; Hong SD; Seo MY; Baek CH; Jeong HS; Chung MK
Surgery; 2010 Sep; 148(3):526-31. PubMed ID: 20189620
[TBL] [Abstract][Full Text] [Related]
22. [Prospective analysis of the risk factors and clinical indications of dissection of lymph node posterior to right recurrent laryngeal nerve in 283 cases of papillary thyroid carcinoma].
Zhang P; Zhang B; Bu J; Liu Y; Zhang W
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):109-14. PubMed ID: 24796458
[TBL] [Abstract][Full Text] [Related]
23. Unilateral Multifocality Is Not a Risk Factor for Recurrence After Thyroid Lobectomy: A Study of 1,684 Patients With Differentiated Thyroid Cancer.
Cho JS; Kim HK
In Vivo; 2023; 37(4):1802-1808. PubMed ID: 37369469
[TBL] [Abstract][Full Text] [Related]
24. Cervical Lymph Node Metastases of Papillary Thyroid Carcinoma, in the Central and Lateral Compartments, in Children and Adolescents: Predictive Factors.
Spinelli C; Tognetti F; Strambi S; Morganti R; Massimino M; Collini P
World J Surg; 2018 Aug; 42(8):2444-2453. PubMed ID: 29383423
[TBL] [Abstract][Full Text] [Related]
25. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
27. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.
Ricarte-Filho J; Ganly I; Rivera M; Katabi N; Fu W; Shaha A; Tuttle RM; Fagin JA; Ghossein R
Thyroid; 2012 Jun; 22(6):575-84. PubMed ID: 22471242
[TBL] [Abstract][Full Text] [Related]
28. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
29. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
30. Long-term Outcomes of cN0 Papillary Thyroid Carcinoma without Elective Central Compartment Neck Dissection.
Zhou B; Huang H; Xu Z; Wu Y; Wang X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Jun; 39(3):383-388. PubMed ID: 28695810
[TBL] [Abstract][Full Text] [Related]
31. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
32. Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer.
Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
Medicine (Baltimore); 2018 Dec; 97(51):e13435. PubMed ID: 30572443
[TBL] [Abstract][Full Text] [Related]
33. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
34. Incidence and clinical characteristics of prelaryngeal lymph node metastasis in papillary thyroid cancer.
Lee YC; Shin SY; Kwon KH; Eun YG
Eur Arch Otorhinolaryngol; 2013 Sep; 270(9):2547-50. PubMed ID: 23553243
[TBL] [Abstract][Full Text] [Related]
35. An Evaluation of Clinicopathological Factors Effective in the Development of Central and Lateral Lymph Node Metastasis in Papillary Thyroid Cancer.
Aydin Buyruk B; Kebapci N; Yorulmaz G; Buyruk A; Kebapci M
J Natl Med Assoc; 2018 Aug; 110(4):384-390. PubMed ID: 30126565
[TBL] [Abstract][Full Text] [Related]
36. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma.
Moo TA; McGill J; Allendorf J; Lee J; Fahey T; Zarnegar R
World J Surg; 2010 Jun; 34(6):1187-91. PubMed ID: 20130868
[TBL] [Abstract][Full Text] [Related]
37. Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection.
Ryu YJ; Cho JS; Yoon JH; Park MH
World J Surg Oncol; 2018 Oct; 16(1):205. PubMed ID: 30314503
[TBL] [Abstract][Full Text] [Related]
38. Factors Affecting the Locoregional Recurrence of Conventional Papillary Thyroid Carcinoma After Surgery: A Retrospective Analysis of 3381 Patients.
Suh YJ; Kwon H; Kim SJ; Choi JY; Lee KE; Park YJ; Park DJ; Youn YK
Ann Surg Oncol; 2015 Oct; 22(11):3543-9. PubMed ID: 25743326
[TBL] [Abstract][Full Text] [Related]
39. Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma.
Feng JW; Yang XH; Wu BQ; Sun DL; Jiang Y; Qu Z
Clin Transl Oncol; 2019 Nov; 21(11):1482-1491. PubMed ID: 30879178
[TBL] [Abstract][Full Text] [Related]
40. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
